Barbarot, SWollenberg, ASilverberg, J IDeleuran, MPellacani, GArmario-Hita, J CChen, ZShumel, BEckert, LGadkari, ALu, YRossi, A B2023-02-082023-02-082020-06-08http://hdl.handle.net/10668/15459Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is approved for treatment of moderate-to-severe AD in Europe, USA, Japan and several other countries. To assess dupilumab effects on SCORing Atopic Dermatitis (SCORAD) and component scores (objective and subjective SCORAD) over time in adults with moderate-to-severe AD. This post hoc analysis included 2,444 patients in four placebo-controlled, double-blind, randomized, phase 3 trials. SOLO 1 and 2 (NCT02277743; NCT02277769) evaluated 16 weeks of dupilumab monotherapy against placebo. CAFÉ (NCT02755649) and CHRONOS (NCT02260986) evaluated dupilumab with concomitant topical corticosteroids (TCS) against TCS alone for 16 and 52 weeks, respectively. 2,444 patients randomized to treatment in SOLO 1 and 2 (N = 1,379), CAFÉ (N = 325) and CHRONOS (N = 740) were analyzed. Dupilumab treatment significantly improved overall SCORAD and individual components as early as Week 1 or 2, with significant and clinically meaningful differences vs. control through end of treatment (p  In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. placebo or TCS alone.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AdultsSCORADatopic dermatitisdupilumabAdultAntibodies, Monoclonal, HumanizedDermatitis, AtopicDouble-Blind MethodHumansSeverity of Illness IndexTreatment OutcomeDupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.research article32347763open access10.1080/09546634.2020.17505501471-1753https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1750550?needAccess=true